<qa>  How many patients will be needed for the phase I portion of the study?For the phase I portion, standard 33 dose escalationde-escalation design will be applied. Approximately 15 to 21 patients will be needed to establish the recommended phase II dose RP2D. For the phase II portion of the study, up to 35 patients will be treated at the RP2D MTD including 6 patients treated at RP2D in phase I. Patients may remain on treatment with the combination until disease progression or unmanageable toxicity. 